Leading the future of radioimmunotherapy for cancer treatment

Leading the future of radioimmunotherapy for cancer treatment

Our CEO, Professor Marika Nestor discusses advancing cancer treatment through radioimmunotherapy in a new interview ahead of her presentation at Antibody Engineering & Therapeutics. The interview highlights Akiram’s recent milestone: the approval of a Phase 1 clinical trial for 177Lu-AKIR001, a novel radiolabeled antibody targeting cancers with high CD44v6 expression, including head and neck squamous cell carcinoma.

The discussion explores how targeted radioimmunotherapy addresses both primary tumours and metastatic lesions, marking a significant innovation in next-generation cancer therapies—a key focus of Akiram’s development programme.

Read the full interview from Antibody Engineering & Therapeutics here.